<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097487</url>
  </required_header>
  <id_info>
    <org_study_id>H2251n</org_study_id>
    <nct_id>NCT00097487</nct_id>
  </id_info>
  <brief_title>A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane</brief_title>
  <official_title>Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a Phase IV, prospective, nonrandomized, community-based study of clinical
      outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2000</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>1000</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastases</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Available tissue for central laboratory evaluation of HER2 status

          -  Histologically confirmed, measurable or nonmeasurable but evaluable, HER2 positive
             metastatic breast cancer (HER2 positive is defined as 3+ staining by IHC or gene
             amplification by FISH, determined by the local or central laboratory)

          -  Life expectancy &gt;6 months

          -  Female, age &gt;=18 years

          -  ECOG performance status of 0, 1, or 2

          -  Adequate bone marrow function as indicated by the following: *ANC &gt;1500/uL, *Platelet
             count &gt;=100,000/uL

          -  Adequate renal function, as indicated by creatinine &lt;=1.5× upper limit of normal
             (ULN)

          -  Adequate liver function, as indicated by bilirubin &lt;=1.5× ULN and AST or ALT &lt;2× ULN
             unless related to primary disease

          -  Use of an adequate means of birth control (women of childbearing potential)

        Exclusion Criteria:

          -  Initiation of Herceptin &gt;=4 weeks after beginning taxane chemotherapy

          -  Prior chemotherapy for metastatic disease

          -  Prior cumulative anthracycline dose of &gt;360 mg/m2

          -  History of significant cardiac disease or uncontrolled arrhythmias

          -  Ejection fraction of &lt;50% or below the lower limit of normal

          -  Active infection

          -  Symptomatic or untreated brain metastases

          -  Pregnancy or lactation

          -  Concomitant malignancies or previous malignancies within the last 5 years, with the
             exception of adequately treated basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs,
             resulting in dyspnea at rest

          -  Hypersensitivity to study medications

          -  Major organ failure or systemic disease precluding the safe administration of study
             medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2004</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>November 24, 2004</firstreceived_date>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
